ACIU (AC Immune) Institutional Ownership: 24.64% (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACIU AC Immune SA ACIU
25 GF Score
Price $2.20
GF Value $0.75
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AC Immune Institutional Ownership?

AC Immune ACIU +0.46% 25 Institutional Ownership is 24.64% as of Jul. 19, 2026. GuruFocus rates ACIU with a GF Score™ of 25/100 and a GF Value™ of $0.75 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AC Immune's institutional ownership is 24.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AC Immune's Insider Ownership is 0.12%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AC Immune's Float Percentage Of Total Shares Outstanding is 47.96%.

AC Immune Institutional Ownership Historical Data

* Premium members only.

The historical data trend for AC Immune's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AC Immune Institutional Ownership Chart

AC Immune Historical Data

The historical data trend for AC Immune can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-06-30
Institutional Ownership 1.09 1.04 1.07 1.01 0.91 0.94 1.01 1.03 1.07 0.98
ACIU
25GF Score
AC Immune SA ACIU
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AC Immune Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 24.64% mean?
AC Immune (ACIU) has a Institutional Ownership of 24.64% as of Jul. 19, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on AC Immune and its competitors.
Is AC Immune's Institutional Ownership too high?
AC Immune's current Institutional Ownership is 24.64%. Overall, AC Immune has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AC Immune's Institutional Ownership compare to NAUT and IVVD?
AC Immune's Institutional Ownership of 24.64% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on AC Immune and its competitors. AC Immune's current Institutional Ownership is 24.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (ACIU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.75, compared to a current price of $2.20 — trading 193.3% above its estimated fair value. The current Institutional Ownership is 24.64%. AC Immune's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For AC Immune (ACIU), the current Institutional Ownership is 24.64% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AC Immune (ACIU) Overvalued in 2026?

Based on GuruFocus' analysis, AC Immune stock appears to be overvalued. The current stock price of $2.20 is trading 193.3% above its estimated GF Value™ of $0.75. GuruFocus considers AC Immune to be Significantly Overvalued.

Key valuation signals for ACIU:

  • Institutional Ownership: 24.64%
  • GF Value™: $0.75 vs. price of $2.20 (193.3% above fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AC Immune Business Description

Other Exchanges IMR:Germany
Address EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
25GF Score

Get the complete analysis for ACIU

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.20
Price
$0.75
GF Value